A Review on Natural Fibre-Reinforced Biopolymer Composites: Properties and Applications

In ongoing decades, material researchers and scientists are giving more consideration towards the improvement of biobased polymer composites as various employments of items arranged by natural fibres and petrochemical polymers prompt natural awkwardness. The goal of this review paper is to provide an intensive review and applications of the foremost appropriate commonly used biodegradable polymer composites. It is imperative to build up the completely/incompletely biodegradable polymer composites without bargaining the mechanical, physical, and thermal properties which are required for the end-use applications. This reality roused to create biocomposite with better execution alongside the least natural effect. The utilization of natural fibre-reinforced polymer composites is concerned with the mechanical properties that are highly dependent on the morphology, hydrophilic tendency, aspect ratio, and dimensional stability of the natural fibre. With this in-depth consideration of eco-friendly biocomposites, structural application materials in the infrastructure, automotive industry, and consumer applications of the following decade are attainable within the near future.

Outcomes and regional differences in practice in a worldwide coronary stent registry

ObjectiveThe primary objective was to assess the performance of a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer in an all comer population. The secondary objective was to detail differences in contemporary percutaneous coronary intervention (PCI) practice worldwide.Methodse-Ultimaster was an all-comer, prospective, global registry (NCT02188355) with independent event adjudication enrolling patients undergoing PCI with the study stent. The primary outcome measure was target lesion failure (TLF) at 1 year, defined as the composite of cardiac death, target vessel myocardial infarction and clinically driven target lesion revascularisation. Data were stratified according to 4 geographical regions.ResultsA total of 37 198 patients were enrolled (Europe 69.2%, Asia 17.8%, Africa/Middle East 6.6% and South America/Mexico 6.5%) and 1-year follow-up was available for 35 389 patients (95.1%). One-year TLF occurred in 3.2% of the patients, ranging from 2% (Africa/Middle East) to 4.1% (South America/Mexico). In patients with acute coronary syndrome, potent P2Y12 inhibitors were prescribed in 48% of patients at discharge, while at 1 year 72% were on any dual antiplatelet therapy. Lipid-lowering treatment was administered in 80.9% and 75.5% of patients at discharge and 1 year, respectively. Regional differences in the profile of the treated patients as well as in PCI practice were reported.ConclusionsIn this investigation with worldwide representation, contemporary PCI using a new generation thin-strut sirolimus-eluting coronary stent with abluminal biodegradable polymer was associated with low 1-year TLF across clinical presentations and continents. Suboptimal adherence to current recommendations around antiplatelet and lipid lowering treatments was detected.